E Fund Management Co., Ltd. Immuno Gen, Inc. Transaction History

E Fund Management Co., Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$12.46 - $29.95 $158,017 - $379,825	-12,682 Reduced 43.54%	16,443 $487,000
Q3 2023 Nov 13, 2023	BUY	$14.09 - $19.87 $154,877 - $218,411	10,992 Added 60.62%	29,125 $462,000
Q2 2023 Aug 11, 2023	SELL	$3.75 - $20.05 $223,237 - $1.19 Million	-59,530 Reduced 76.65%	18,133 $342,000
Q1 2023 May 11, 2023	BUY	$3.67 - $4.92 $21,865 - $29,313	5,958 Added 8.31%	77,663 $298,000
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $29,925 - $41,500	6,577 Added 10.1%	71,705 $356,000
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $92,449 - $133,514	-20,636 Reduced 24.06%	65,128 $311,000
Q2 2022 Aug 15, 2022	BUY	$3.15 - $5.76 $135,380 - $247,553	42,978 Added 100.45%	85,764 $386,000
Q1 2022 May 12, 2022	BUY	$4.26 - $7.48 $124,979 - $219,448	29,338 Added 218.16%	42,786 $204,000
Q4 2021 Feb 11, 2022	SELL	$4.75 - $7.5 $15,912 - $25,125	-3,350 Reduced 19.94%	13,448 $100,000
Q3 2021 Nov 12, 2021	BUY	$5.02 - $6.59 $5,788 - $7,598	1,153 Added 7.37%	16,798 $95,000
Q1 2021 May 12, 2021	BUY	$6.5 - $10.53 $101,692 - $164,741	15,645 New	15,645 $126,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.